"Totality-of-the-evidence" of proposed ustekinumab biosimilar SB17"

被引：0
|
作者：
Armuzzi, A. [1 ]
Girolomoni, G. [2 ]
Feldman, S. [3 ]
Goncalves, J. [4 ]
Park, Y. [5 ]
Ye, B. D. [6 ]
机构：
[1] IRCCS Humanitas Res Hosp, IBD Ctr, Milan, Italy
[2] Univ Verona, Dermatol, Verona, Italy
[3] Wake Forest Univ, Sch Med, Dermatol, Winston Salem, NC USA
[4] Univ Lisbon, Fac Pharm, Lisbon, Portugal
[5] Samsung Bioepis Co Ltd, Med Affairs, Incheon, South Korea
[6] Univ Ulsan, Coll Medicin, Gastroenterol Inflammatory Bowel Dis Ctr, Asan Med Ctr, Seoul, South Korea
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1019
引用
收藏
页码：I1832 / I1834
页数：3
相关论文
共 50 条
  • [41] Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method
    Hyunsoo Kim
    Eunkyoung Hong
    Jungmin Lee
    Seokku Hong
    Jihye Kim
    Miju Cho
    Yikwon Kim
    Taekyung Yoo
    [J]. BioDrugs, 2023, 37 : 569 - 581
  • [42] Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method
    Kim, Hyunsoo
    Hong, Eunkyoung
    Lee, Jungmin
    Hong, Seokku
    Kim, Jihye
    Cho, Miju
    Kim, Yikwon
    Yoo, Taekyung
    [J]. BIODRUGS, 2023, 37 (04) : 569 - 581
  • [43] Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions
    Dongkuk Park
    Jihyun Kim
    Jihoon Yun
    Su Jin Park
    [J]. Advances in Therapy, 2020, 37 : 4308 - 4324
  • [44] A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC
    Reck, M.
    Luft, A.
    Bondarenko, I.
    Shevnia, S.
    Trukhin, D.
    Kovalenko, N. V.
    Vacharadze, K.
    Andrea, F.
    Hontsa, A.
    Choi, J.
    Shin, D.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [45] A Randomized, Double-blind, Phase III Study to Compare SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients with Postmenopausal Osteoporosis
    Eastell, Richard
    Langdahl, Bente
    Chung, Yoon-Sok
    Plebanski, Rafal
    Czerwinski, Edward
    Dokoupilova, Eva
    Supronik, Jerzy
    Rosa, Jan
    Rowinska-Osuch, Anna
    Baek, Ki-Hyun
    Urboniene, Audrone
    Ahn, Sohui
    Rho, Younghee
    Ban, Jisuk
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3960 - 3961
  • [46] Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naive or Switching Patients: A Systematic Review
    Ebbers, Hans C.
    Pieper, Burkhard
    Issa, Amine
    Addison, Janet
    Freudensprung, Ulrich
    Rezk, Mourad F.
    [J]. RHEUMATOLOGY AND THERAPY, 2019, 6 (03) : 317 - 338
  • [47] A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence
    Macaluso, Fabio Salvatore
    Cummings, J. R. Fraser
    Atreya, Raja
    Choi, Jaeyun
    Orlando, Ambrogio
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (02) : 203 - 223
  • [48] When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab
    Damiani, Giovanni
    Conic, Rosalynn R. Z.
    de Vita, Valerio
    Costanzo, Antonio
    Regazzini, Roberto
    Pigatto, Paolo D. M.
    Bragazzi, Nicola L.
    Pacifico, Alessia
    Malagoli, Piergiorgio
    [J]. DERMATOLOGIC THERAPY, 2019, 32 (02)
  • [49] Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
    Hans C. Ebbers
    Burkhard Pieper
    Amine Issa
    Janet Addison
    Ulrich Freudensprung
    Mourad F. Rezk
    [J]. Rheumatology and Therapy, 2019, 6 : 317 - 338
  • [50] Exploratory analyses of efficacy from a phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC
    Planchard, D.
    Shin, D.
    Choi, J.
    Seo, Y.
    Jung, J. A.
    Park, M.
    Reck, M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S877 - S878
12345